Influence factors on HBV relapse after withdrawal of nucleos(t)ide analogues treatment

被引：0
|
作者：
Zhang, Ka [1 ]
Liang, Yijia [1 ]
Sun, Xiahai [1 ]
Pan, Feixing [1 ]
Xu, Huanqi [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷
关键词：
Chronic Hepatitis B; Influence Factors; Withdrawal; Relapse;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [21] Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues
    Leung, Nancy
    HEPATOLOGY INTERNATIONAL, 2008, 2 (02) : 163 - 178
  • [22] Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues
    Buster, Erik H. C. J.
    Schalm, Solko W.
    Janssen, Harry L. A.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2008, 22 (06) : 1093 - 1108
  • [23] TOLERABILITY AND EFFICACY OF ANTI-HBV NUCLEOS(T)IDE ANALOGUES IN CIRRHOTIC PATIENTS WITH HBV-HCV COINFECTION
    Coppola, Nicola
    Stanzione, Maria
    Messina, Vincenzo
    De Pascalis, Stefania
    Pisaturo, Mariantonietta
    Macera, Margherita
    Tonziello, Gilda
    Fiore, Marco
    Sagnelli, Caterina
    Pasquale, Giuseppe
    Sagnelli, Evangelista
    HEPATOLOGY, 2011, 54 : 1057A - 1057A
  • [24] Reply to: "Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels"
    Sonneveld, Milan J.
    Chiu, Shao-Ming
    Chen, Chien-Hung
    Maasoumy, Benjamin
    JOURNAL OF HEPATOLOGY, 2022, 77 (04) : 1224 - 1226
  • [25] USING OFF-TREATMENT HBV DNA LEVELS TO PREDICT ALT RELAPSE AFTER NUCLEOS(T)IDE ANALOGUE DISCONTINUATION: A PROSPECTIVE COHORT STUDY
    Chi, H.
    Cao, J.
    Hansen, B. E.
    Yu, T.
    Cai, S.
    Li, Z.
    Janssen, H. L.
    Peng, J.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S589 - S589
  • [26] HBV Vaccine Escape Mutations in a Chronic Hepatitis B Patient Treated with Nucleos(t)ide Analogues
    Sayan, Murat
    Bugdaci, Mehmet Sait
    MIKROBIYOLOJI BULTENI, 2013, 47 (03): : 544 - 549
  • [27] Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma
    Yu, Yiqi
    Ai, Jingwen
    Zhang, Wenhong
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (10) : 925 - 937
  • [28] HBeAg-positive patients with HBsAg  < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
    Yandi Xie
    Minghui Li
    Xiaojuan Ou
    Sujun Zheng
    Yinjie Gao
    Xiaoyuan Xu
    Ying Yang
    Anlin Ma
    Jia Li
    Yuan Huang
    Yuemin Nan
    Huanwei Zheng
    Bo Feng
    Journal of Gastroenterology, 2021, 56 : 856 - 867
  • [29] HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
    Xie, Yandi
    Li, Minghui
    Ou, Xiaojuan
    Zheng, Sujun
    Gao, Yinjie
    Xu, Xiaoyuan
    Yang, Ying
    Ma, Anlin
    Li, Jia
    Huang, Yuan
    Nan, Yuemin
    Zheng, Huanwei
    Feng, Bo
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (09) : 856 - 867
  • [30] Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
    Jiang, Bei
    Dai, Qinghai
    Liu, Yamin
    Yu, Guangxin
    Mi, Yuqiang
    INFECTIOUS AGENTS AND CANCER, 2022, 17 (01)
12345